DARA Biosciences (NASDAQ: DARA) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, valuation, risk, analyst recommendations and institutional ownership.
Earnings and Valuation
This table compares DARA Biosciences and Eagle Pharmaceuticals’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Eagle Pharmaceuticals||$189.48 million||4.47||$81.45 million||$6.21||9.15|
Risk & Volatility
DARA Biosciences has a beta of 0.72, meaning that its share price is 28% less volatile than the S&P 500. Comparatively, Eagle Pharmaceuticals has a beta of 1.25, meaning that its share price is 25% more volatile than the S&P 500.
This table compares DARA Biosciences and Eagle Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a breakdown of current ratings and target prices for DARA Biosciences and Eagle Pharmaceuticals, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Eagle Pharmaceuticals has a consensus price target of $63.67, indicating a potential upside of 12.07%. Given Eagle Pharmaceuticals’ higher possible upside, analysts clearly believe Eagle Pharmaceuticals is more favorable than DARA Biosciences.
Eagle Pharmaceuticals beats DARA Biosciences on 9 of the 9 factors compared between the two stocks.
About DARA Biosciences
DARA BioSciences Inc is specialty pharmaceutical company based in the United States. The Company’s primary focus is on the commercialization of oncology treatment and oncology supportive care pharmaceutical products, including Soltamox, an oral solution of tamoxifen citrate; cancer support therapeutics, including Gelclair, indicated for the treatment of oral mucositis and Bionect, for the management of irritation of the skin as well as first and second degree burns, and Three Mission Pharmacal products, including Ferralet 90 (for anemia), Binosto (alendronate sodium effervescent tablet indicated for the treatment of osteoporosis) and Aquoral (for cancer related dry mouth). The Company has a clinical development asset, KRN5500, which is a Phase II product candidate targeted for treating cancer patients with painful treatment-refractory chronic chemotherapy induced peripheral neuropathy. The Company is a subsidiary of Midatech Pharma Plc.
About Eagle Pharmaceuticals
Eagle Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing injectable products in the critical care and oncology areas. The Company’s product portfolio includes products, including Argatroban; Ryanodex; docetaxel injection, non-alcohol formulation; and Bendeka. Its advanced candidates include EP-3101 (bendamustine Resistance Temperature Detectors (RTD)) (EP-3101), EP-4104 (dantrolene sodium for exertional heat stroke (EHS)) (EP-4104), EGL-4104-C-1702 (dantrolene sodium for drug induced hyperthermia), EP-5101 (pemetrexed) (EP-5101) and EGL-5385-C-1701 (fulvestrant). Its product portfolio focuses on oncology, critical care and orphan diseases. Bendamustine is an alkylating agent approved for use in chronic lymphocytic leukemia (CLL), and indolent B-cell non-Hodgkin’s lymphoma (NHL), that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Receive News & Ratings for DARA Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DARA Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.